Status:
COMPLETED
Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients
Lead Sponsor:
UCB Pharma
Collaborating Sponsors:
International Bureau for Epilepsy
Conditions:
Epilepsy
Eligibility:
All Genders
4+ years
Brief Summary
The purpose of the survey is to explore through a structured interview and patient examination the rate and distribution of neurological and systemic adverse effects related to antiepileptic treatment...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male and female patients from the age of 4 years
- Confirmed diagnosis of epilepsy requiring AED treatment
- Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide
- Treatment must be stable for at least 3 months prior to assessment
- Absence of other severe and/or uncontrolled symptomatic chronic illness
Exclusion
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00394927
Start Date
April 1 2007
End Date
August 1 2007
Last Update
July 19 2012
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna, Austria
2
Blansko, Czechia
3
České Budějovice, Czechia
4
Hradec Králové, Czechia